Bionano Genomics, Inc. (BNGO)
| Previous Close | 5.28 |
| Open | 5.36 |
| Bid | 0.00 x 21500 |
| Ask | 0.00 x 40700 |
| Day's Range | 5.13 - 5.36 |
| 52 Week Range | 0.47 - 15.69 |
| Volume | 8,568,348 |
| Avg. Volume | 10,345,511 |
| Market Cap | 1.477B |
| Beta (5Y Monthly) | 1.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings Date | Nov. 10, 2021 - Nov. 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
- GlobeNewswire
Study Finds the Combination of Optical Genome Mapping and Short-Read Sequencing Provides a Comprehensive Genome Analysis for Lung Cancer Samples and Enables the Discovery of New Biomarkers
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study finding the combination of optical genome mapping (OGM) and short-read next-generation sequencing (NGS) provides a comprehensive genome analysis for lung cancer samples and enables the discovery of new biomarkers. This study, appearing in the September 7th peer-reviewed issue of Cell Reports describes how the combination of OGM and NGS aids in the detection of structural variants (SVs) in
- Motley Fool
4 Small-Cap Growth Stocks Expected to Increase Sales 707% to 9,406% by 2024
These under-the-radar companies are expected to deliver jaw-dropping revenue growth over the next four years.
- GlobeNewswire
NuProbe Global Adopts Bionano’s Saphyr® System to Develop Products in Reproductive Health and Oncology Applications
SAN DIEGO and SHANGHAI, China, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, has adopted Bionano’s Saphyr system for optical genome mapping (OGM) to integrate their Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA) technologies for research and product development in the fields of reproductive health and oncology l
